NEW YORK (GenomeWeb) — Illumina may be the dominant microarray vendor but that hasn't stopped some from pondering the future of its BeadChip business given the San Diego company's focus on next-generation sequencing.

During a presentation at Bank of America Merrill Lynch's Healthcare Conference in Las Vegas last week, analysts asked CEO Jay Flatley about Illumina's intentions for its array business, which continues to register single-digit quarterly growth even as it has been overshadowed by Illumina's activities in the sequencing market.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers are refining a tool to predict a woman's risk of developing breast cancer, according to the Guardian.

According to Stat News, the partial government shutdown in the US could soon affect the ability of the Food and Drug Administration to review new drugs.

In PNAS this week: gypsy moth genome sequenced, phylogenomic analysis of Polyneopterans, and more.

CNN reports that people's genes tend to have a greater influence on their risk of developing disease than their environment, but it varies by phenotype.